"Exemptia is a Fingerprint Match of Adalimumab. The Data is now Published."
"Exemptia is Approved in Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis,
Plaque Psoriasis, Hidradenitis Suppurativa, Crohn’s Disease, Paediatric Crohn's Disease and Ulcerative Colitis”
Open/Close Menu
Exemptia | Adalimumab Biosimilar of Adalimumab
Skip to content
  • About Adalimumab
  • Important Safety Instructions
  • Medication Guide
  • Instructions for Use
  • Voice of Exemptia
  • Health Care Professionals

Downloads Home | Important Links | Downloads


Medication Guide


Instructions for Use


Patient Education Booklet

Latest News

  • Exemptia Phase- III Clinical Trial is now published July 14, 2015
  • EXEMPTIA biosimilarity article is now published January 16, 2015
  • Click here to view the Exemptia Launch movie December 9, 2014
  • Click here to access the Press note about Adalimumab December 9, 2014
  • Zydus launches world’s first biosimilar of Adalimumab December 9, 2014

Contact Us

Exemptia

Toll free: 1800-123-CARE

1800-123-2273

care@exemptia.com

Information from Zydus

  • About Zydus
  • Zydus Innovation programme
  • Adalimumab
  • Adalimumab Biosimilar
  • Adverse Event Reporting
  • Site Map

Conditions

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Hidradenitis Suppurativa
  • Crohn's Disease & Ulcerative Colitis

Important Links

  • Healthcare Professional Site
  • ExemptiaTM Care – Patient Support Programme
  • Important Safety Instructions
  • Prescribing Information
  • Downloads

Contact us

Zydus Tower,
Satellite Cross Roads,
Ahmedabad – 380015
Gujarat, India.

Toll free: 1800-123-CARE (1800-123-2273)

E-mail: care@exemptia.com


© 2018 Cadila Healthcare Ltd. All Rights Reserved. | CompuBrain

↑

